Patents by Inventor Ying Qin ZANG

Ying Qin ZANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CEACAM5-dependent 4-1BB-agonistic bispecific antibodies
    Patent number: 12247081
    Abstract: Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.
    Type: Grant
    Filed: May 8, 2024
    Date of Patent: March 11, 2025
    Assignee: LANOVA MEDICINES LIMITED
    Inventors: Runsheng Li, Wei Cao, Ying Qin Zang, Wentao Huang
  • BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF
    Publication number: 20250019442
    Abstract: Provided are bispecific antibodies capable of binding to human VEGF protein and human PD-1 protein. These bispecific antibodies are effective in treating cancer.
    Type: Application
    Filed: September 26, 2024
    Publication date: January 16, 2025
    Inventors: Runsheng Li, Wei CAO, Haijuan GU, Wentao HUANG, Ying Qin ZANG
  • Antibodies targeting LIV-1 and uses thereof
    Patent number: 12194106
    Abstract: Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1. SLC39A6 or ZIP6) protein as well as their derivatives and uses.
    Type: Grant
    Filed: May 6, 2024
    Date of Patent: January 14, 2025
    Assignee: LANOVA MEDICINES LIMITED
    Inventors: Runsheng Li, Wentao Huang, Ying Qin Zang, Zhifang Liu, Yifan Li
  • Antibodies and antibody-drug conjugates targeting claudin 6
    Patent number: 12180276
    Abstract: Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.
    Type: Grant
    Filed: May 6, 2024
    Date of Patent: December 31, 2024
    Assignee: LANOVA MEDICINES LIMITED
    Inventors: Runsheng Li, Wentao Huang, Ying Qin Zang, Zhifang Liu
  • ANTIBODIES TARGETING LIV-1 AND USES THEREOF
    Publication number: 20240325555
    Abstract: Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1, SLC39A6 or ZIP6) protein as well as their derivatives and uses.
    Type: Application
    Filed: May 6, 2024
    Publication date: October 3, 2024
    Inventors: Runsheng Li, Wentao Huang, Ying Qin Zang, Zhifang LIU, Yifan Li
  • ANTIBODIES AND ANTIBODY-DRUG CONJUGATES TARGETING CLAUDIN 6
    Publication number: 20240317851
    Abstract: Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.
    Type: Application
    Filed: May 6, 2024
    Publication date: September 26, 2024
    Inventors: Runsheng Li, Wentao Huang, Ying Qin Zang, Zhifang LIU
  • CEACAM5-DEPENDENT 4-1BB-AGONISTIC BISPECIFIC ANTIBODIES
    Publication number: 20240294656
    Abstract: Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.
    Type: Application
    Filed: May 8, 2024
    Publication date: September 5, 2024
    Inventors: Runsheng Li, Wei Cao, Ying Qin Zang, Wentao Huang
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20240262841
    Abstract: The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.
    Type: Application
    Filed: February 6, 2024
    Publication date: August 8, 2024
    Inventors: Runsheng LI, Wentao HUANG, Zhifang LIU, Ying Qin ZANG
  • BISPECIFIC ANTIBODIES TARGETING SIRPa AND PD-L1
    Publication number: 20240101716
    Abstract: Provided are antibodies and fragments having binding specificity to the signal regulatory protein alpha (SIRP?) protein and to the programmed death-ligand 1 (PD-L1) protein. The antibodies and fragments can bring peripheral macrophages to PD-L1+ tumor site, thereby enhancing tumor treatment.
    Type: Application
    Filed: December 17, 2021
    Publication date: March 28, 2024
    Inventors: Runsheng LI, Ying Qin ZANG